Comorbidity in Adult Psoriasis: Considerations for the Clinician

Abstract

Psoriasis is associated with several comorbidities ranging from cardiovascular comorbidity and mental disorders to other immune mediated inflammatory diseases. However, most of these co-morbidities are often overlooked or diagnosed late. Furthermore, evidence suggests that comorbidities are undertreated. Here, we provide an overview of comorbidities in psoriasis and present a simple rundown of considerations of relevance to the clinician. We hope that this review may raise clinicians’ awareness of comorbidities in psoriasis and provide simple guidance regarding screening tools and treatment decisions in psoriasis with comorbidities.

Keywords:

• psoriasis
• comorbidities
• clinician guidelines

Acknowledgments

Louise Faurskov Møller was co-developer of Figure 1.

Disclosure

Lars Iversen has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by: AbbVie, Almirall, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo Pharma, MSD, Novartis, Pfizer, Regranion, Samsung, Union Therapeutics, UCB. Kasper Hjuler has been a consultant and advisor for the following companies: AbbVie, Bristol Myers Squibb (BMS), Janssen, LEO Pharma, UCB, Novartis and has received speaking fees or grants from: AbbVie, Eli Lilly, LEO Pharma, Novartis, Janssen. The authors report no other conflicts of interest in this work.